Table 1.

Completed Trials of Radiosensitizers in the Temozolomide Era

First Author	NCT No.	Design	Patients, No.	Drug	Completed Study Drug + RT plus TMZ, %	Grade 3 Toxicity, n	Grade 4 Toxicity, n	Grade 5 Toxicity, n	Late-Grade 3 to 5 Toxicity, %	Delayed RT, %	6-Mo PFS, %	Median PFS, mo	Median OS, mo
Stupp, 200216		Phase 2 single-arm	64	TMZ	86	22	40	–	–	30	–	–	16
Stupp, 20054	NCT00006353	Phase 3 randomized	287	TMZ	85	7% grade 3/4	–	–	1	32	54	–	14.6
Brown, 200817	NCT00039494	Phase 2 single-arm	97	Erlotinib	84	105	24	2	–	–	–	7.2	15.3
Prados, 200918	NCT00187486	Phase 2 single-arm	65	Erlotinib	–	43	5	0	–	–	73	8.2	19.3
Peereboom, 201019	NCT00274833	Phase 2 single-arm	28	Erlotinib	74	31	5	4	–	–	30	2.8	8.6
NCCTG N057K Ma, 201520	NCT00553150	Phase 1/2 single-arm	100	Everolimus	78	–	–	1	–	–	–	6.4	15.8
RTOG 0913 Chinnaiyan, 201821	NCT01062399	Phase 1/2 randomized	171	Everolimus	–	108	39	10	–	–	–	8.2	16.5
Krauze, 201522	NCT00302159	Phase 2 single-arm	37	Valproate	67	16	6	0	223	0	70	10.5	29.6
Galanis, 201824	NCT00731731	Phase 1/2 single-arm	107	Vorinostat	–	106	47	3	–	–	–	8.0	16.1
Butowski, 201125	NCT00402116	Phase 1/2 single-arm	66	Enzastaurin	–	66% grade 3/4	–	5	–	–	65	8.4	17.3
Lee, 201526	NCT00441142	Phase 1/2 randomized	76	Vandenatib	67	93 ≥ grade 3	–	1	–	–	58	7.7	16.6
Butowski, 200527		Phase 2 single-arm	61	13-cis-retinoic acid	92	18	8	0	–	–	38	4.9	13.3
Grossman, 200928		Phase 2 single-arm	72	Talampanel	–	38	15	1	–	–	–	–	18.3
Kong, 201829	NCT00998010	Phase 2 single-arm	24	Bortezomib	–	9	1	0	–	–	54	6.2	19.1

Abbreviations: NCCTG, North Central Cancer Treatment Group; NCT, national clinical trial; OS, overall survival; PFS, progression-free survival; RT, radiation; RTOG, Radiation Therapy Oncology Group; TMZ, temozolomide.